CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $244,546 | -5.4% | 4,356 | -23.8% | 0.23% | -4.1% |
| Q1 2023 | $258,625 | +11.3% | 5,718 | 0.0% | 0.24% | +22.7% |
| Q4 2022 | $232,437 | -37.9% | 5,718 | 0.0% | 0.20% | -43.8% |
| Q3 2022 | $374,000 | +4.2% | 5,718 | 0.0% | 0.35% | +27.5% |
| Q1 2022 | $359,000 | -29.2% | 5,718 | -14.5% | 0.28% | -23.3% |
| Q4 2021 | $507,000 | -43.7% | 6,687 | -16.8% | 0.36% | -49.2% |
| Q3 2021 | $900,000 | -30.0% | 8,037 | +1.2% | 0.71% | -28.6% |
| Q2 2021 | $1,286,000 | +33.5% | 7,943 | +0.5% | 0.99% | +25.4% |
| Q1 2021 | $963,000 | -26.0% | 7,901 | -7.1% | 0.79% | +79.1% |
| Q4 2020 | $1,302,000 | +32.5% | 8,505 | -27.6% | 0.44% | +7.6% |
| Q3 2020 | $983,000 | +41.8% | 11,748 | +24.6% | 0.41% | +15.5% |
| Q2 2020 | $693,000 | – | 9,428 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |